

Luiz Everson da Silva,<sup>a</sup>  
Carla Regina Andrighetti-  
Fröhner,<sup>a</sup> Ricardo José Nunes,<sup>a</sup>  
Cláudia Maria Oliveira Simões<sup>b</sup>  
and Sabine Foro<sup>c\*</sup>

<sup>a</sup>Departamento de Química—UFSC, 88040-900 Florianópolis, SC, Brazil, <sup>b</sup>Departamento de Ciências Farmacêuticas—UFSC, 88040-900 Florianópolis, SC, Brazil, and <sup>c</sup>Clemens Schöpf-Institut für Organische Chemie und Biochemie, Technische Universität Darmstadt, Petersenstrasse 22, D-64287 Darmstadt, Germany

Correspondence e-mail: foro@tu-darmstadt.de

#### Key indicators

Single-crystal X-ray study  
T = 299 K  
Mean  $\sigma(\text{C—C}) = 0.004 \text{ \AA}$   
R factor = 0.045  
wR factor = 0.132  
Data-to-parameter ratio = 13.0

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

## Quinolin-8-yl 2,5-dichlorobenzenesulfonate


In the title compound,  $\text{C}_{15}\text{H}_9\text{Cl}_2\text{NO}_3\text{S}$ , the torsion angle about the O—S bond between the quinoline system and the benzene ring is  $146.2(2)^\circ$ . One weak intermolecular C—H $\cdots$ O hydrogen bond is observed in the crystal structure.

Received 10 April 2006

Accepted 25 April 2006

#### Comment

Quinoline derivatives have been reported to show broad-spectrum efficacy against multiple herpes viruses and they may have a potential role for the treatment of a variety of infections, such as those caused by herpes simplex virus type 1 (Hartline *et al.*, 2005; Oliveira *et al.*, 2004), human cytomegalovirus and varicella zoster virus (Oien *et al.*, 2002; Knechtel *et al.*, 2002). As part of our screening programme to investigate antiviral activity (Andrighetti-Fröhner *et al.*, 2003; Savi *et al.*, 2005), we report here an X-ray crystallographic study of the title compound, (I).



The key feature of the molecular structure of (I) (Fig. 1) is the C1—O1—S1—C10 torsion angle of  $146.2(2)^\circ$ , which illustrates the non-planarity of the molecule. The H atom on atom C3 of the quinoline ring system has one intermolecular contact to a sulfonyl O atom (H $\cdots$ O =  $2.54 \text{ \AA}$ ), forming a three-dimensional network (Fig. 2 and Table 1).


#### Experimental

The title compound was prepared by the reaction of one equivalent of 8-hydroxyquinoline and 1.1 equivalents of 2,5-dichlorobenzene-sulfonyl chloride in the presence of pyridine (2 ml) overnight, according to the literature procedure of Kimber *et al.* (2003). Single crystals of (I) suitable for X-ray data collection were obtained by recrystallization from a solution in methanol–dichloromethane (1:1).

#### Crystal data

$\text{C}_{15}\text{H}_9\text{Cl}_2\text{NO}_3\text{S}$   
 $M_r = 354.19$   
Monoclinic,  $P2_1/c$   
 $a = 7.842(1) \text{ \AA}$   
 $b = 25.536(3) \text{ \AA}$   
 $c = 7.642(1) \text{ \AA}$   
 $\beta = 107.87(1)^\circ$   
 $V = 1456.5(3) \text{ \AA}^3$

$Z = 4$   
 $D_x = 1.615 \text{ Mg m}^{-3}$   
Cu  $K\alpha$  radiation  
 $\mu = 5.46 \text{ mm}^{-1}$   
 $T = 299(2) \text{ K}$   
Prism, colourless  
 $0.53 \times 0.30 \times 0.23 \text{ mm}$



**Figure 1**  
The molecular structure of (I), with 50% probability displacement ellipsoids (arbitrary spheres for H atoms).

#### Data collection

Enraf–Nonius CAD-4  
diffractometer  
 $\omega/2\theta$  scans  
Absorption correction:  $\psi$  scan  
(North *et al.*, 1968)  
 $T_{\min} = 0.129$ ,  $T_{\max} = 0.285$   
3088 measured reflections

2593 independent reflections  
2301 reflections with  $I > 2\sigma(I)$   
 $R_{\text{int}} = 0.029$   
 $\theta_{\text{max}} = 67.0^\circ$   
3 standard reflections  
frequency: 120 min  
intensity decay: 1.0%

#### Refinement

Refinement on  $F^2$   
 $R[F^2 > 2\sigma(F^2)] = 0.045$   
 $wR(F^2) = 0.132$   
 $S = 1.07$   
2593 reflections  
200 parameters  
H-atom parameters constrained

$w = 1/[\sigma^2(F_o^2) + (0.0696P)^2 + 0.9445P]$   
where  $P = (F_o^2 + 2F_c^2)/3$   
 $(\Delta/\sigma)_{\text{max}} < 0.001$   
 $\Delta\rho_{\text{max}} = 0.38 \text{ e } \text{\AA}^{-3}$   
 $\Delta\rho_{\text{min}} = -0.60 \text{ e } \text{\AA}^{-3}$   
Extinction correction: *SHELXL97*  
(Sheldrick, 1997)  
Extinction coefficient: 0.0045 (5)


**Table 1**

Hydrogen-bond geometry ( $\text{\AA}$ ,  $^\circ$ ).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
$C3-H3\cdots O2^i$	0.93	2.54	3.294 (4)	138

Symmetry code: (i)  $x, -y + \frac{1}{2}, z + \frac{1}{2}$ .

All H atoms were positioned with idealized geometry, with  $C-H = 0.93 \text{ \AA}$ , and refined in riding mode, with  $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$ .



**Figure 2**  
The packing of (I), showing the hydrogen bonding (dashed lines).

Data collection: *CAD-4-PC* (Enraf–Nonius, 1993); cell refinement: *CAD-4-PC*; data reduction: *REDU4* (Stoe & Cie, 1987); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *PLATON* (Spek, 2003); software used to prepare material for publication: *SHELXL97*.

The authors thank Professor Dr Hartmut Fueß, Technische Universität Darmstadt, for diffractometer time.

#### References

- Andrighetti-Fröhner, C. R., Antonio, R. V., Creczynski-Pasa, T. B., Barardi, C. R. & Simões, C. M. O. (2003). *Mem. Inst. Oswaldo Cruz*, **98**, 843–848.
- Hartline, C. B., Harden, E. A., Williams-Aziz, S. L., Kushner, N. L., Brideau, R. J. & Kern, E. R. (2005). *Antivir. Res.* **65**, 97–105.
- Kimber, M. C., Geue, J. P., Lincoln, S. F., Ward, A. D. & Tiekink, E. R. T. (2003). *Aust. J. Chem.* **56**, 39–44.
- Knechtel, M. L., Huang, A., Vaillancourt, V. A. & Brideau, R. J. (2002). *J. Med. Virol.* **68**, 234–236.
- Nonius (1993). *CAD-4-PC*. Version 1.2. Nonius, Delft, The Netherlands.
- North, A. C. T., Phillips, D. C. & Mathews, F. S. (1968). *Acta Cryst.* **A24**, 351–359.
- Oien, N. L., Brideau, R. J., Hopkins, T. A., Wieber, J. L., Knechtel, M. L., Shelly, J. A., Anstadt, R. A., Wells, P. A., Poorman, R. A., Huang, A., Vaillancourt, V. A., Clayton, T. L., Tucker, J. A. & Wathen, M. W. (2002). *Antimicrob. Agents Chemother.* **46**, 724–730.
- Oliveira, M. R., Alves, T. R., Pinto, A. C., de Pereira, H. S., Leão-Ferreira, L. R., Moussatché, N., de Frugulhetti, I. C. P. P., Ferreira, V. F. & de Souza, M. C. B. V. (2004). *Nucleosides Nucleotides Nucleic Acids*, **23**, 735–748.
- Savi, L. A., Leal, P. C., Vieira, T. O., Rosso, R., Nunes, R. J., Yunes, R. A., Creczynski-Pasa, T. B., Barardi, C. R. & Simões, C. M. O. (2005). *Arzneim.-Forsch. (Drug Res.)*, **55**, 66–75.
- Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
- Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.
- Stoe & Cie (1987). *REDU4*. Version 6.2c. Stoe & Cie GmbH, Darmstadt, Germany.